Detalhe da pesquisa
1.
BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor.
Blood
; 2024 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38437498
2.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441846
3.
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.
Blood
; 141(11): 1265-1276, 2023 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36265087
4.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724453
5.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Blood
; 141(6): 567-578, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36399715
6.
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Lancet Oncol
; 25(3): 388-399, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38423051
7.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591430
8.
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
Br J Haematol
; 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603594
9.
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
Br J Haematol
; 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38724457
10.
Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2.
Blood
; 139(6): 907-921, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34601571
11.
An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis.
Blood
; 139(7): 1098-1110, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34780598
12.
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Blood
; 140(1): 58-72, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390143
13.
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Blood
; 140(16): 1753-1763, 2022 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512188
14.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695144
15.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
16.
The role of therapy in the outcome of patients with myelofibrosis.
Cancer
; 129(18): 2828-2835, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37243913
17.
Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
Cancer
; 129(4): 531-540, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477735
18.
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
Cancer
; 129(2): 175-180, 2023 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36397669
19.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
20.
Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.
Cancer
; 129(7): 1017-1029, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36715486